Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?

Crit Care. 2020 Jun 8;24(1):311. doi: 10.1186/s13054-020-03023-0.
No abstract available

Publication types

  • Editorial

MeSH terms

  • COVID-19
  • Clinical Trials as Topic
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Hospitalization
  • Humans
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Proteinase Inhibitory Proteins, Secretory / therapeutic use*
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / virology*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Proteinase Inhibitory Proteins, Secretory